Real-World Study to Track Oral Semaglutide Safety and Effectiveness in Type 2 Diabetes
Background
Globally, Type 2 Diabetes Mellitus (T2DM) remains a significant public health challenge, requiring effective and convenient long-term management strategies. Oral semaglutide (Rybelsus), a GLP-1 receptor agonist, offers a non-injectable option for glycemic control. However, comprehensive real-world data on its safety and effectiveness in routine clinical practice, particularly within the Korean population, is still being systematically gathered.
Study Design
Results
As a 'not yet recruiting' study, specific findings are not available, but the study is designed to generate crucial real-world data. It will primarily evaluate the safety profile of oral semaglutide by monitoring the incidence and characteristics of adverse drug reactions (ADRs) in 600 patients over 26 weeks. The study also aims to assess the effectiveness of Rybelsus by tracking changes in key glycemic parameters, including HbA1c, and body weight. The overarching goal is to confirm the safety and effectiveness of oral semaglutide when used in routine clinical practice among Korean adults with Type 2 Diabetes Mellitus, providing quantitative insights into its real-world performance.
Why It Matters
This regulatory post-marketing surveillance study is crucial for gathering real-world evidence on oral semaglutide, complementing data from controlled clinical trials. Such data is vital for understanding how the drug performs in diverse patient populations and under varying clinical conditions, which can differ significantly from trial settings. The findings could support broader clinical adoption, refine treatment guidelines, and enhance physician confidence in prescribing Rybelsus for Type 2 Diabetes management.